Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — FY2023 Earnings Presentation
31 slides from Gufic Biosciences's earnings presentation, May 29, 2023
Slide 1: Exchange filing cover letter
108/LG/SE/MAY/2023/GBSL May 29, 2023 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code : 509079 Scrip Symbol : GUFICBIO Dear Sir/Madam, Subject: In
Slide 2: Delivering Care & Cure - Investor Presentation May 2023
Delivering Care & Cure Investor Presentation May 2023
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosc iences Limited (the “ Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions. This prese ntation does not constitute or form part of any offer or invitation
Slide 4: FY23 Business & Financial Highlights
FY23 Business & Financial Highlights
Slide 5: FY23 Business Highlights
FY23 Business Highlights Gearing up for Indore Facility to go live Domestic Business Breakup • We continue to invest in the R&D for molecules to be commercialized at Indore facility. This will reduce our time to market. We anticipate that the validation of the facility will be completed by September
Slide 6: FY23 Business Highlights
FY23 Business Highlights Ferticare Division • Dydrogesterone : This product has was launched in Q2FY23. Further, to de-risk the short supply of API, Gufic has vertically integrated to manufacture its own API. We are also in the process of launching a sustained release form of Dydrogesterone in FY24.
Slide 7: FY23 Business Highlights
FY23 Business Highlights Aestherderm Division • Successfully completed a split face trial between Stunnox and Botox. Stunnox continues to increase penetration in the market and Gufic is now 2nd largest player for Botulinum Toxin. • Initiated the process of registration for a range of fillers to comp
Slide 8: FY23 Business Highlights
FY23 Business Highlights International Business • Have seen growth of ~25% through International Business. 190+ Products are now registered across regulated and semi-regulated markets • Another 150+ products are in pipeline for registration in over 40 countries • Cleared the ANVIZA-Brazil audit succ
Slide 9: Innovation at Gufic
Innovation at Gufic Update on Research & Development and Innovation • The API Research Development at Navsari has made noteworthy progress in development of molecules in therapeutic categories such as Antifungal, Anticoagulant, Tetracycline Antibiotics, Progestin, Beta 3 adrenegic agonists, Antidiab
Slide 10: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 11: Profit & Loss Statement
Profit & Loss Statement Pa r t i c u l a rs ( i n R s . C r o re) FY23 FY22* Q4 FY23 Q4 FY22* To ta l Rev e n u e 690.6 779.2 173.0 162.2 E B I T DA 137.2 151.1 32.8 32.7 E B I T DA M a r g i n % 19.9% 19.4% 18.9% 20.2% P ro f i t b efo re Ta x 106.7 126.8 23.9 26.2 P BT M a r g i n s % 15.5% 16.3%
Slide 12: Company Overview
Company Overview
Slide 13: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 14: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Amphotericin B and Depot Injections Natura
Slide 15: Upcoming World Class Manufacturing Infrastructure
Upcoming World Class Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Civil Construction and Site Development work is Facility Carbapenems (Lyophilized / Dry progressing as per schedule and is near comple
Slide 16: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 17: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s Field Force: 250 Field Force: >150 Field Force: >180 200+ Therapy Areas: Antibacterial, Therapy Areas: Hormones, Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 18: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 19: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 20: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 21: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 22: Extensive Sales, Distribution & IT Infrastructure
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure Retail coverage of more than 23 Carrying & Forwarding (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 23: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 24: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 25: Historical Financials
Historical Financials
Slide 26: Historical Financials
Historical Financials Total Revenue EBITDA & EBITDA Margin Profit After Tax & PAT Margin 13.1% 13.8% 17.2% 19.4% 19.9% 5.4% 6.3% 6.0% 12.3% 11.5% 779 691 151 96 137 488 80 379 351 84 44 52 46 22 23 2019 2020 2021 FY22* FY23 2019 2020 2021 FY22* FY23 2019 2020 2021 FY22 FY23 CAGR 18% CAGR 31% CAGR 38
Slide 27: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY23 FY22 FY21 FY20 FY19 FY18 Revenue from Operations 690.6 779.2 487.7 378.8 350.8 305.6 EBITDA 137.2 151.1 83.9 52.1 46.0 38.8 EBITDA Margin % 19.9% 19.4% 17.2% 13.8% 13.1% 12.7% Profit before Tax 106.7 126.8 57.7 30.1 35.3 30.0 PBT Margin % 15.5% 16.3%
Slide 28: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 9.7 9.7 9.7 9.7 7.8 Other Equity 338.1 259.4 163.7 119.6 67.6 Total Equity 347.8 269.1 173.4 129.3 75.3 Non-Current Liabilities Financial Liabilities i. Borrowings
Slide 29: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 126.8 105.5 93.8 72.7 24.1 Intangible assets 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 169.6 40.9 13.4 30.6 9.6 Right of use assets 32.1 9.1 5.8 9.3 0.0 Financia
Slide 30: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 106.7 126.9 44.2 22.7 21.9 Adjustments for: Non - Cash Items / Other Investment or 29.6 23.2 44.3 32.1 26.8 Financial Items Operating profit before working capital changes 136.4 150.0 88.5 54.8 48.7 C
Slide 31: Thank You
THANK YOU Company: Gufic Biosciences Limited Investor Relations Advisors: Strategic Growth Advisors (SGA) CIN: L24100MH1984PLC033519 CIN: U74140MH2010PTC204285 Mr. Avik Das – Investor Relations Mr. Deven Dhruva / Mr. Harsh Shah avik.das@guficbio.com deven.dhruva@sgapl.net / harsh.shah@sgapl.net Tel: